New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients

While an estimated 95% of “younger” patients diagnosed with Hodgkin lymphoma are still alive and into survivorship within five years of their diagnosis, their long-term health suffers from the aggressive treatment needed to fight the disease.

  • November 10, 2025

Share

  • 1

    The new Phase 3 clinical trial, AHOD2131, aims to reduce long-term treatment complications in Hodgkin lymphoma patients.

  • 2

    Immunotherapy is being incorporated to decrease the intensity of conventional chemotherapy and radiation therapy.

  • 3

    The trial is open to pediatric and adult patients aged 5 to 60 with stage 1 or 2 Hodgkin lymphoma.

  • 4

    The study anticipates that only 15% of patients will require radiation, significantly lower than historical rates.

  • 5

    The trial aims to enroll 1,875 patients over five years and includes correlative studies on treatment response and tolerability.

Original Source(s)

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients

  • November 10, 2025

Related Content

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min
Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology